Skip to main content
. 2010 Apr 14;2010(4):CD002300. doi: 10.1002/14651858.CD002300.pub2

Van Eygen 1989(b).

Methods Trial III referred to above. Please see above for details.
Participants  
Interventions  
Outcomes  
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence generation? Unclear risk Details not given.
Allocation concealment? Unclear risk Unclear
Blinding? 
 All outcomes Unclear risk "under double‐blind conditions, the medications being identical in appearance and taste" p670. Further details not given.